secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2026-08-12T12:35:13+00:00
Accession:  0001104659-26-094542
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Q2 2026: net loss $3.6M, cash $41.2M, APR-1051 enrollment accelerating
----------------------------------------------------------------------------

- Cash $41.2M at June 30, 2026 vs $14.6M at Dec 31, 2025; runway into Q1 2028.
- Net loss $3.6M ($0.07/share) on 53.5M shares vs $3.2M ($0.53/share) on 6.1M shares in Q2 2025.
- APR-1051 Phase 1 trial sites expand 3 to 10; enrollment 6-10 patients/month by Q4 2026; next data at Q4 2026 medical meeting.
- Plans to advance APR-1051 in USC and Cyclin E-overexpressing PROC; combinations in HPV+ head/neck and colorectal cancer.
- $30M private placement closed Q1 2026; ATRN-119 study closed, combinations under discussion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926094542/0001104659-26-094542-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926094542/apre-20260812x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-094542

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer